Tamoxifen reduces risk of breast cancer in high risk patientsBMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7383.244/a (Published 01 February 2003) Cite this as: BMJ 2003;326:244
- Debashis Singh
Prophylactic use of tamoxifen over five years reduces the incidence of breast cancer by 38% in healthy women with a high risk of developing the disease, a study published in the Lancet says (2003;361:296-300).
The authors, from Cancer Research UK, conducted an extensive review of 14 trials involving over 40 000 women. Four of the trials tested the role of tamoxifen as a preventive treatment in 28 000 women, and another trial, involving 7700 women, tested the role of raloxifene instead. Both drugs were compared with a placebo. In nine trials 15 000 women who had had a tumour removed from one breast were treated with tamoxifen to prevent the cancer returning.
The study found that in healthy women with a high chance of developing the disease tamoxifen reduced the incidence …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial